14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
BLLN vs TWST: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, BillionToOne, Inc. (BLLN) is the stronger overall head-to-head candidate over Twist Bioscience Corporation (TWST) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BLLN carries a Unified Composite Score of 45.8/100 (HOLD) at $96.31 (61.3x Forward P/E, 10.2% operating margin), whereas TWST carries 51.7/100 (HOLD) at $105.04 (N/M Forward P/E, -28.8% operating margin).
Composite vs. Pillar Nuance: While TWST currently prints a higher short-term Unified Composite Score (51.7/100 HOLD vs. BLLN 45.8/100 HOLD), BLLN captures the overall institutional head-to-head verdict (7–3 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (10.2% vs. -28.8% operating margin) and revenue trajectory (+47.2% vs. +27.9% YoY).
Technical & Structure Timing Caution: BLLN is currently in a Breakdown options structure phase (RSI 34.4); meanwhile TWST trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 35.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Biotechnology value chain with $7.4B market capitalization and -28.8% operating margin.
OpEx & R&D Reinvestment81.2% of Rev ($373M)
90D Engineering Disclosures0 Published · Spatial Genomics
Investor FAQ BLLN vs TWST Key Questions & Quantitative Answers
As of Nov 16, 2026, BillionToOne, Inc. (BLLN) is the stronger overall head-to-head candidate over Twist Bioscience Corporation (TWST) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BLLN carries a Unified Composite Score of 45.8/100 (HOLD) at $96.31 (61.3x Forward P/E, 10.2% operating margin), whereas TWST carries 51.7/100 (HOLD) at $105.04 (N/M Forward P/E, -28.8% operating margin). Composite vs. Pillar Nuance: While TWST currently prints a higher short-term Unified Composite Score (51.7/100 HOLD vs. BLLN 45.8/100 HOLD), BLLN captures the overall institutional head-to-head verdict (7–3 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (10.2% vs. -28.8% operating margin) and revenue trajectory (+47.2% vs. +27.9% YoY). Technical & Structure Timing Caution: BLLN is currently in a Breakdown options structure phase (RSI 34.4); meanwhile TWST trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 35.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
BLLN leads the Growth & Scale pillar: BLLN posts +47.2% YoY revenue growth and +220.0% YoY earnings growth on $437M TTM revenue (71.4% gross margin, 10.2% operating margin), compared with TWST at +27.9% YoY revenue growth and +0.0% YoY earnings growth on $459M TTM revenue (52.4% gross margin, -28.8% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), BLLN cumulative revenue shifted +342.9% while TWST shifted +1166.7%. In operating R&D and SG&A reinvestment, BLLN deploys 61.2% of Rev ($267M) (0 90-day corporate R&D disclosures) versus 81.2% of Rev ($373M) (0 disclosures) for TWST.
BLLN screens cheaper on headline valuation multiples. BLLN trades at 61.3x Forward P/E, 114.3x Trailing P/E, N/M PEG, and 10.5x EV/Revenue (7.8% FCF margin), whereas TWST trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 16.1x EV/Revenue (-23.4% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BLLN (13.2% ROE) versus TWST (-19.1% ROE) capital efficiency.
In options market volatility and institutional positioning, BLLN carries 113.8% implied volatility (26th %ile, Balanced (25th–60th %ile)), a 1.21x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.44β · 42% Vol realized risk). By comparison, TWST carries 100.1% implied volatility (19th %ile, Compressed (<25th %ile)), a 1.04x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (3.13β · 126% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.